文献速递糖尿病

HypoCOMPaSS试验两年随访:优化自我管理可持久减少1型糖尿病伴低血糖感知受损成人的严重低血糖

Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial.
PubMed 文献 · Diabetes Care · 2018-04-16

HypoCOMPaSS随机试验纳入96例1型糖尿病伴低血糖感知受损成人,随机接受泵或每日多次注射、实时连续血糖监测或自我血糖监测,各组均接受同等教育关注。24周后回归常规照护随访至24个月,低血糖感知改善持续,严重低血糖从研究前12个月的8.9次/人年降至24个月内的0.4次/人年,HbA1c改善,各干预间无显著差异。

要点

  • 低血糖感知Gold评分从基线5.1±1.1持续改善至24个月3.7±1.9(P<0.0001)。
  • 严重低血糖从研究前12个月8.9±12.8次/人年降至24个月内的0.4±0.8次/人年(P<0.0001)。
  • HbA1c从基线8.2±3.2%(66±12 mmol/mol)改善至24个月7.7±3.1%(61±10 mmol/mol)(P=0.003)。

核心结论

  • 优化胰岛素替代和血糖监测并以低血糖为重点的结构化教育为基础,应提供给所有1型糖尿病伴低血糖感知受损者。

研究设计与样本

  • 英国五家三级转诊糖尿病中心招募96例1型糖尿病(病程29±12年)伴低血糖感知受损成人。
  • 24周2×2析因随机对照试验,随机分配至泵(CSII)或每日多次注射(MDI),以及实时连续血糖监测(RT-CGM)或自我血糖监测(SMBG),各组教育关注相等。
  • 24周后回归常规照护随访至24个月,包括自由选择MDI/CSII,RT-CGM与SMBG比较持续至24个月。

主要发现

  • 低血糖感知改善持续:Gold评分基线5.1±1.1 vs 24个月3.7±1.9(P<0.0001)。
  • 严重低血糖率从研究前12个月8.9±12.8次/人年降至24个月内的0.4±0.8次/人年(P<0.0001)。
  • HbA1c改善:基线8.2±3.2%(66±12 mmol/mol)vs 24个月7.7±3.1%(61±10 mmol/mol)(P=0.003)。
  • 治疗满意度改善和低血糖恐惧减少持续。
  • 24个月时各干预间无显著差异。

关键数值与推荐

  • 主要结局为低血糖感知从基线至24个月的平均差异(组间)。
  • 低血糖感知Gold评分基线5.1±1.1 vs 24个月3.7±1.9(P<0.0001)。
  • 严重低血糖研究前12个月8.9±12.8次/人年 vs 24个月内0.4±0.8次/人年(P<0.0001)。
  • HbA1c基线8.2±3.2%(66±12 mmol/mol)vs 24个月7.7±3.1%(61±10 mmol/mol)(P=0.003)。

临床怎么用

  • 作者认为,以低血糖为重点的结构化教育为基础,优化胰岛素替代和血糖监测应提供给所有1型糖尿病伴低血糖感知受损者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Severe hypoglycemia is a feared complication of type 1 diabetes; yet, few trials have targeted prevention using optimized self-management (educational, therapeutic, and technological support). We aimed to investigate whether improved awareness and reduced severe hypoglycemia, achieved during an intensive randomized clinical trial (RCT), were sustained after return to routine care. RESEARCH DESIGN AND METHODS: Ninety-six adults with type 1 diabetes (29 ± 12 years' duration) and impaired awareness of hypoglycemia at five U.K. tertiary referral diabetes centers were recruited into a 24-week 2 × 2 factorial RCT (HypoCOMPaSS). Participants were randomized to pump (continuous subcutaneous insulin infusion [CSII]) or multiple daily injections (MDIs) and real-time continuous glucose monitoring (RT-CGM) or self-monitoring of blood glucose (SMBG), with equal education/attention to all groups. At 24 weeks, participants returned to routine care with follow-up until 24 months, including free choice of MDI/CSII; RT-CGM vs. SMBG comparison continued to 24 months. Primary outcome was mean difference (baseline to 24 months [between groups]) in hypoglycemia awareness. RESULTS: Improvement in hypoglycemia awareness was sustained (Gold score at baseline 5.1 ± 1.1 vs. 24 months 3.7 ± 1.9; P < 0.0001). Severe hypoglycemia rate was reduced from 8.9 ± 12.8 episodes/person-year over the 12 months prestudy to 0.4 ± 0.8 over 24 months (P < 0.0001). HbA1c improved (baseline 8.2 ± 3.2% [66 ± 12 mmol/mol] vs. 24 months 7.7 ± 3.1% [61 ± 10 mmol/mol]; P = 0.003). Improvement in treatment satisfaction and reduced fear of hypoglycemia were sustained. There were no significant differences between interventions at 24 months. CONCLUSIONS: Optimized insulin replacement and glucose monitoring underpinned by hypoglycemia-focused structured education should be provided to all with type 1 diabetes complicated by impaired awareness of hypoglycemia.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Little SA, Speight J, Leelarathna L, et al. Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial. Diabetes Care. 2018. PMID: 29661916. doi:10.2337/dc17-2682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。